UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 915

Sortiert nach

11 Everolimus (Rad001) as Treatment in Breast Cancer Patients with Bone Metastases Only – First Results of the Multi-centre, Placebo-controlled, Randomized Discontinuation Phase II RADAR Study

European journal of cancer (1990), 2012-03, Vol.48, p.S43-S43

2012

Volltextzugriff (PDF)

1805 Association between HER2-phenotype on circulating tumor cells and primary tumor characteristics in women with metastatic breast cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S266-S266

2015

Volltextzugriff (PDF)

18P A translational project of the WSG-ADAPT-TN trial demonstrates immunomodulatory and anti-viral defense gene networks predicting pathological complete response (pCR) and survival after de-escalated neoadjuvant chemotherapy (NACT) in early triple-negative breast cancer (eTNBC)

ESMO open, 2023-05, Vol.8 (1), p.101242, Article 101242

2023

Volltextzugriff (PDF)

191 DETECT III – a Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells

European journal of cancer (1990), 2012-03, Vol.48, p.S95-S96

2012

Volltextzugriff (PDF)

1937 Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG phase III planB trial

European journal of cancer (1990), 2015-09, Vol.51, p.S311-S311

2015

Volltextzugriff (PDF)

218 DOES DIABETES AFFECT THE DISTRIBUTION OF INTERSTITIAL CELLS AND NEURONAL TISSUE IN THE BLADDER, PROSTATE AND URETHRA OF RABBITS?

European urology supplements : official journal of the European Association of Urology, 2009-03, Vol.8 (4), p.175-175

2009

Volltextzugriff (PDF)

256: Hematopoietic stem cell transplantation for hematological diseases at Yeditepe University Hospital

Biology of blood and marrow transplantation, 2007, Vol.13 (2), p.94-94

2007

Volltextzugriff (PDF)

394 IMPORTANCE OF THE THORACOLUMBAR JUNCTION (MAIGNE) SYNDROME IN LOW BACK PAIN

European journal of pain, 2006-09, Vol.10 (S1), p.S105b-S105

2006

Volltextzugriff (PDF)

536 The effect of trapidil on long term histological damage in ischemia-reperfusion injury of the testis

European urology supplements : official journal of the European Association of Urology, 2004-02, Vol.3 (2), p.136-136

2004

Volltextzugriff (PDF)

IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia

Bratislavské lékarské listy, 2019-01, Vol.66 (11), p.819-826

2019

Volltextzugriff (PDF)

893 RATE AND TYPE OF LIVER INJURY AFTER BMT MAY DEPEND ON THE CONDITIONING REGIMEN IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Journal of hepatology, 2008, Vol.48, p.S335-S335

2008

Volltextzugriff (PDF)

9103 The radioprotective effect of dimethyl sulfoxide in radiation induced acute pulmonary injury: detection by Tc99m-DTPA transalveolar clearance scintigraphy and histopathology

European journal of cancer supplements, 2009, Vol.7 (2), p.535-535

2009

Volltextzugriff (PDF)

Ab initio design of half-metallic fully compensated ferrimagnets: The case of Cr 2 Mn Z ( Z = P , As, Sb, and Bi)

Physical review. B, Condensed matter and materials physics, 2007-05, Vol.75 (17), Article 172405

2007

Volltextzugriff (PDF)

Ablation of hemodynamically unstable ventricular tachycardia guided by ultra-high density pacemapping and PASO correlation map, a multi-center clinical trial

Europace (London, England), 2024-05, Vol.26 (Supplement_1)

2024

Volltextzugriff (PDF)

Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.GS3-05-GS3-05

2018

Volltextzugriff (PDF)

Abstract GS5-06: No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.GS5-06-GS5-06

2019

Volltextzugriff (PDF)

Abstract OT1-02-02: The DETECT study program – Personalized treatment in metastatic breast cancer based on circulating tumor cells

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.OT1-02-02-OT1-02-02

2016

Volltextzugriff (PDF)

Abstract OT1-02-04: The DETECT V-study – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT1-02-04-OT1-02-04

2017

Volltextzugriff (PDF)

Abstract OT1-1-10: DETECT III - A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumorcells

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.OT1-1-10-OT1-1-10

2012

Volltextzugriff (PDF)

Abstract OT3-04-02: DETECT III and IV – Individualized CTC-based therapy of metastatic breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT3-04-02-OT3-04-02

2017

Volltextzugriff (PDF)

Abstract P1-01-09: Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor, synchronous axillary lymph node metastases and circulating tumor cells in early breast cancer patients

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P1-P1-01-09

2017

Volltextzugriff (PDF)

Abstract P1-04-13: The role of excision repair cross-complementation 1 enzyme (ERCC1)-positive circulating tumor cells in primary and metastatic breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P1-P1-04-13

2013

Volltextzugriff (PDF)

Abstract P1-09-05: The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P1-P1-09-05

2017

Volltextzugriff (PDF)

Abstract P1-11-01: Effectiveness, safety and quality of life (QoL) results from the German multicenter AVANTI study of 1st-line bevacizumab (BEV)-containing therapy in >2000 patients (pts) with advanced breast cancer (aBC)

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-11-01

2018

Volltextzugriff (PDF)

Abstract P1-13-01: Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P1-P1-13-01

2016

Volltextzugriff (PDF)

1 – 25 von 915

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieAnnals Of Oncology

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(815)
Mit Volltextzugriff
(871)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(469)
Physics
(215)
Physical Sciences
(208)
Life Sciences & Biomedicine
(197)
Technology
(163)
Humans
(100)
Physics, Condensed Matter
(86)
Materials Science
(72)
Exact Sciences And Technology
(66)
Physics, Applied
(57)
Female
(55)
Materials Science, Multidisciplinary
(55)
Engineering
(54)
Male
(54)
Animals
(48)
Biological And Medical Sciences
(48)
Condensed Matter: Electronic Structure, Electrical, Magnetic, And Optical Properties
(46)
Medical Sciences
(37)
Magnetic Properties And Materials
(33)
Computer Science
(31)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

11 Everolimus (Rad001) as Treatment in Breast Cancer Patients with Bone Metastases Only – First Results of the Multi-centre, Placebo-controlled, Randomized Discontinuation Phase II RADAR Study

1805 Association between HER2-phenotype on circulating tumor cells and primary tumor characteristics in women with metastatic breast cancer

18P A translational project of the WSG-ADAPT-TN trial demonstrates immunomodulatory and anti-viral defense gene networks predicting pathological complete response (pCR) and survival after de-escalated neoadjuvant chemotherapy (NACT) in early triple-negative breast cancer (eTNBC)

191 DETECT III – a Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells

1937 Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG phase III planB trial

218 DOES DIABETES AFFECT THE DISTRIBUTION OF INTERSTITIAL CELLS AND NEURONAL TISSUE IN THE BLADDER, PROSTATE AND URETHRA OF RABBITS?

256: Hematopoietic stem cell transplantation for hematological diseases at Yeditepe University Hospital

394 IMPORTANCE OF THE THORACOLUMBAR JUNCTION (MAIGNE) SYNDROME IN LOW BACK PAIN

536 The effect of trapidil on long term histological damage in ischemia-reperfusion injury of the testis

IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia

893 RATE AND TYPE OF LIVER INJURY AFTER BMT MAY DEPEND ON THE CONDITIONING REGIMEN IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

9103 The radioprotective effect of dimethyl sulfoxide in radiation induced acute pulmonary injury: detection by Tc99m-DTPA transalveolar clearance scintigraphy and histopathology

Ab initio design of half-metallic fully compensated ferrimagnets: The case of Cr 2 Mn Z ( Z = P , As, Sb, and Bi)

Ablation of hemodynamically unstable ventricular tachycardia guided by ultra-high density pacemapping and PASO correlation map, a multi-center clinical trial

Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69

Abstract GS5-06: No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial

Abstract OT1-02-02: The DETECT study program – Personalized treatment in metastatic breast cancer based on circulating tumor cells

Abstract OT1-02-04: The DETECT V-study – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer

Abstract OT1-1-10: DETECT III - A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumorcells

Abstract OT3-04-02: DETECT III and IV – Individualized CTC-based therapy of metastatic breast cancer

Abstract P1-01-09: Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor, synchronous axillary lymph node metastases and circulating tumor cells in early breast cancer patients

Abstract P1-04-13: The role of excision repair cross-complementation 1 enzyme (ERCC1)-positive circulating tumor cells in primary and metastatic breast cancer

Abstract P1-09-05: The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC)

Abstract P1-11-01: Effectiveness, safety and quality of life (QoL) results from the German multicenter AVANTI study of 1st-line bevacizumab (BEV)-containing therapy in >2000 patients (pts) with advanced breast cancer (aBC)

Abstract P1-13-01: Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial

Aktive Filter

Suchergebnisse filtern